This is a fully human IgG1 antibody using the same sequences as the therapeutic antibody felzartamab. It is derived from a proprietary antibody phage library, initially developed for the treatment of multiple myeloma, and currently being evaluated in autoimmune disease. Felzartamab is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells. It recruits cells of the body’s immune system to kill the tumor through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).